Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Free Cash Flow (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Free Cash Flow for 6 consecutive years, with -$53.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 31.22% year-over-year to -$53.8 million, compared with a TTM value of -$254.5 million through Sep 2025, down 28.85%, and an annual FY2024 reading of -$208.1 million, down 32.89% over the prior year.
  • Free Cash Flow was -$53.8 million for Q3 2025 at Autolus Therapeutics, up from -$80.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$7.2 million in Q4 2022 and bottomed at -$83.8 million in Q1 2025.
  • Average Free Cash Flow over 4 years is -$49.1 million, with a median of -$46.7 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 264.3% in 2023, then skyrocketed 31.22% in 2025.
  • Year by year, Free Cash Flow stood at -$7.2 million in 2022, then tumbled by 264.3% to -$26.3 million in 2023, then plummeted by 40.02% to -$36.8 million in 2024, then plummeted by 46.12% to -$53.8 million in 2025.
  • Business Quant data shows Free Cash Flow for AUTL at -$53.8 million in Q3 2025, -$80.1 million in Q2 2025, and -$83.8 million in Q1 2025.